Evidence map›Paper›PMID 42273887›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.

Rosalie J Cottez, Clémence Peyrot, Hélèna L Denis, Cyntia Tremblay, Andréanne Loiselle, Caroline Dallaire-Théroux, Ali Filali-Mouhim, Sébastien S Hébert, Nicole Leclerc, Kaj Blennow and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rosalie J CottezNeurosciences Axis, CHU de Québec Research Center, Laval University, Quebec City, Quebec, Canada.ORCID https://orcid.org/0009-0004-6233-9074
Clémence PeyrotInstitut Universitaire de Gériatrie de Montréal Research Center, Montreal, Quebec, Canada.
Hélèna L DenisNeurosciences Axis, CHU de Québec Research Center, Laval University, Quebec City, Quebec, Canada.ORCID https://orcid.org/0000-0003-1978-5058
Cyntia TremblayNeurosciences Axis, CHU de Québec Research Center, Laval University, Quebec City, Quebec, Canada.
Andréanne LoiselleNeurosciences Axis, CHU de Québec Research Center, Laval University, Quebec City, Quebec, Canada.
Caroline Dallaire-ThérouxNeurosciences Axis, CHU de Québec Research Center, Laval University, Quebec City, Quebec, Canada.ORCID https://orcid.org/0000-0003-1729-2209
Ali Filali-MouhimInstitut Universitaire de Gériatrie de Montréal Research Center, Montreal, Quebec, Canada.
Sébastien S HébertNeurosciences Axis, CHU de Québec Research Center, Laval University, Quebec City, Quebec, Canada.
Nicole LeclercCentre Hospitalier de l'Université de Montréal Research Center, Montreal, Quebec, Canada.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Consortium for the Early Identification of Alzheimer's Disease – Quebec (CIMA‐Q)Consortium pour l'Identification Précoce de la Maladie d'Alzheimer-Québec, Montreal, Quebec, Canada.
Marie-Jeanne KergoatInstitut Universitaire de Gériatrie de Montréal Research Center, Montreal, Quebec, Canada.
Frédéric CalonNeurosciences Axis, CHU de Québec Research Center, Laval University, Quebec City, Quebec, Canada.ORCID https://orcid.org/0000-0002-4203-0887
Alexa Pichet BinetteInstitut Universitaire de Gériatrie de Montréal Research Center, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0001-5218-3337

Funding

Consortium for the Neurodegeneration associated with Aging (CCNA)Courtois FoundationEuropean Union's Horizon Europe research and innovation program 101053962European Union's Horizon Europe research and innovation programme under grant agreementFondation de l'Institut de gériatrie de MontréalFondation Famille LemaireFond d'enseignement et de recherche du cercle du congrès de la Faculté de pharmacie, Université LavalFonds de Recherche du Québec (FRQ)FRQ 361227FRQ cohort funds 279261(FRQS) - Pfizer Innovation ProgramQuebec Network for Research on aging (RQRV)Swedish State Support for Clinical Research #ALFGBG-71320the Swedish Research Council 00356the Swedish Research Council 01018the Swedish Research Council 02397
6 · The paper itself

Abstract

introductionWe evaluated associations between phosphorylated au 217 (p-tau217), p-tau181, p-tau231, and vascular risk factors with cognitive outcomes across the Alzheimer's disease (AD) continuum.

methodsBaseline plasma p-tau concentrations and vascular risk factors were assessed in 277 Consortium for the Early Identification of Alzheimer's Disease-Quebec (CIMA-Q) participants. Associations between these markers, cognition, and clinical progression over on average 3.10 years were examined.

resultsHigher plasma p-tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p-tau217 in cognitively impaired individuals (β = -0.49, p < 0.001). Hypertension was further linked to steeper memory and executive function decline (β = -0.10, both p = 0.04) in this group, and it amplified the effect of p-tau217 on cognitive decline across the whole group. Higher p-tau217 levels were associated with cognitive decline in cognitively unimpaired individuals, and it also predicted progression from mild cognitive impairment (MCI) to AD dementia (hazard ratio [HR] = 1.22, p = 0.016). DISCUSSION: Plasma p-tau217 was the most sensitive marker of cognitive decline, with hypertension contributing to longitudinal cognitive changes.

Indexed as

Alzheimer DiseaseCognitive Dysfunctiontau ProteinsAgedBiomarkersCohort StudiesDisease ProgressionFemaleHumansHypertensionMaleNeuropsychological TestsPhosphorylationRisk FactorsBiomarkerstau ProteinsAlzheimer's diseaseclinical progressioncognitionhypertensionlongitudinalmild cognitive impairmentp‐tau217

Identifiers

PMID42273887
PMCPMC13254824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.